Alison Lawton is Chief Operating Officer (COO) at Aura Biosciences Inc. Prior to joining Aura, Alison was COO at OvaScience and before that she spent 23 years in various positions of increasing responsibility at Genzyme Corporation and subsequently as part of Sanofi-Aventis, following its 2011 acquisition of Genzyme. Ms. Lawton served as head of a $1 Billion business, Genzyme Biosurgery, where she was responsible for Genzyme’s global orthopedics, surgical and regenerative medicine businesses. Prior to that, Ms. Lawton oversaw Global Market Access at Genzyme, which encompassed global functions including Regulatory Affairs, Health Outcomes & Strategic Pricing, Public Policy, Product Safety & Risk Management and Quality Systems. Before joining Genzyme, Ms. Lawton worked for seven years in the United Kingdom at Parke-Davis. Ms. Lawton currently serves on the board of directors of Verastem, Inc., ProQR Therapeutics, and CoLucid Pharmaceuticals, all public biopharmaceutical companies, and the private company Follica Inc. She also served on the board of directors of Cubist Pharmaceuticals for three years until its acquisition by Merck &Co., Inc. in 2015. She also currently sits on the Corporate Advisory Board for X4 Pharmaceuticals and is a corporate advisor to Visgo Therapeutics.